Zobrazeno 1 - 10
of 33
pro vyhledávání: '"García García-Porrero A"'
Autor:
Cózar Olmo, J.M., Carballido Rodríguez, J., Rubio-Briones, J., Useros Rodríguez, E., Muñoz del Toro, J. *, García García-Porrero, Á., Juárez-Soto, Á.
Publikováno v:
In Actas Urológicas Españolas (English Edition) April 2021 45(3):198-206
Autor:
P De la Torre, J Collado, Á Alcázar-Garrido, A García-García-Porrero, M Gutiérrez-Vélez, L Forcén Acebal, M Martínez-López, A Masero-Casasola, J Medina Polo, E Muñoz-Gálligo, A Flores
Publikováno v:
Continence, Vol 2, Iss , Pp 1- (2022)
Externí odkaz:
https://doaj.org/article/28f1b9a2fabe40b884782a87c69594cf
Autor:
A. Rodríguez Antolín, L. Martínez-Piñeiro, M. E. Jiménez Romero, J. B. García Ramos, D. López Bellido, J. Muñoz del Toro, A. García García-Porrero, F. Gómez Veiga
Publikováno v:
BMC Urology, Vol 19, Iss 1, Pp 1-8 (2019)
Abstract Background Fatigue is one of the most prevalent symptoms among cancer patients. Specifically, in metastatic castration-resistant prostate cancer (mCRPC) patients, fatigue is the most common adverse event associated with current treatments. T
Externí odkaz:
https://doaj.org/article/41e7b5e50a6347a385ef7e3832765fcd
Autor:
Javier Puente, Aranzazu González-del-Alba, Núria Sala-Gonzalez, María José Méndez-Vidal, Alvaro Pinto, Ángel Rodríguez, José Miguel Cuevas Sanz, Jacobo Rodrigo Muñoz del Toro, Eduardo Useros Rodríguez, Ángela García García-Porrero, Sergio Vázquez
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background To describe the patterns of second-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel treatment in a Spanish population, to identify the factors associated with those patterns,
Externí odkaz:
https://doaj.org/article/7a49a1a1be274ce3b87d79bfb68cdf6a
Autor:
J. Medina-Polo, A.I. Flores, M.J. Perez-Lorenzo, A. Alcazar-Garrido, P. De La Torre, A. García-García-Porrero, M.C. Gutiérrez-Vélez, L. Delapuente-Ovejero, H. García-Muñoz, J. Grande-García, E. Muñoz-Gálligo, A.R. Masero-Casasola
Publikováno v:
European Urology Open Science, Vol 19, Iss , Pp e1614- (2020)
Externí odkaz:
https://doaj.org/article/2344614343534d48a7402a7884c18f92
Autor:
De la Torre, P, Collado, J, Alcázar-Garrido, Á, García-García-Porrero, A, Gutiérrez-Vélez, M, Forcén Acebal, L, Martínez-López, M, Masero-Casasola, A, Medina Polo, J, Muñoz-Gálligo, E, Flores, A
Publikováno v:
In Continence June 2022 2 Supplement 2
Autor:
J M, Cózar Olmo, J, Carballido Rodríguez, J, Rubio-Briones, E, Useros Rodríguez, J, Muñoz Del Toro, Á, García García-Porrero, Á, Juárez-Soto
Publikováno v:
Actas urologicas espanolas. 45(3)
The aim of the study was to describe the clinical drivers that lead physicians to perform imaging tests in search of metastasis in non-metastasic castration prostate resistant cancer (nmCRPC) patients.Observational, cross-sectional study conducted at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b3681fe055aae61f4b1bdb4ff5d5f17f
https://pubmed.ncbi.nlm.nih.gov/33558084
https://pubmed.ncbi.nlm.nih.gov/33558084
Autor:
Alvaro Alcazar-Garrido, Ana Rosa Masero-Casasola, Ana I. Flores, Maria Jesus Perez-Lorenzo, Jesus Grande-García, Huberto García-Muñoz, Eloy Muñoz-Gálligo, P. De La Torre, Maria Carmen Gutiérrez-Vélez, Alicia García-García-Porrero, José Medina-Polo, L. Delapuente-Ovejero
Publikováno v:
European Urology Open Science, Vol 19, Iss, Pp e1614-(2020)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4aa9b9052fec326581da1a7b6a965686
http://www.sciencedirect.com/science/article/pii/S2666168320336776
http://www.sciencedirect.com/science/article/pii/S2666168320336776
Autor:
J. Muñoz del Toro, F. Gómez Veiga, D. Lopez Bellido, A. García García-Porrero, J. B. García Ramos, L. Martínez-Piñeiro, M. E. Jiménez Romero, A. Rodriguez Antolin
Publikováno v:
BMC Urology, Vol 19, Iss 1, Pp 1-8 (2019)
BMC Urology
BMC Urology
Background Fatigue is one of the most prevalent symptoms among cancer patients. Specifically, in metastatic castration-resistant prostate cancer (mCRPC) patients, fatigue is the most common adverse event associated with current treatments. The purpos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36f746be3f24b490b3985d4d00b85cb3
https://doi.org/10.1186/s12894-019-0527-8
https://doi.org/10.1186/s12894-019-0527-8
Autor:
Sergio Vázquez, Jose Miguel Cuevas Sanz, A. González-del-Alba, Alvaro Pinto, Jacobo Muñoz del Toro, Ángela García García-Porrero, Ángel Francisco Zazo Rodríguez, Javier Puente, Eduardo Useros Rodríguez, Núria Sala-González, María José Méndez-Vidal
Publikováno v:
BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
Background To describe the patterns of second-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel treatment in a Spanish population, to identify the factors associated with those patterns, and to co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d270e48a194bc5fa40a33adaee1148d
http://europepmc.org/articles/PMC6683519
http://europepmc.org/articles/PMC6683519